FDA Approval
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
Blueprint Medicines
PR-M11-20-027Dec 02, 2020
Collaboration
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
Blueprint Medicines
PR-M07-20-NI-023Jul 15, 2020
Market Expansion
BluePrint Medicines Targets Asian Market
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M06-18-NI-002Jun 05, 2018